Zepbound Alternatives: Compounded Tirzepatide, Wegovy, Foundayo and Mounjaro, Compared

What are the real alternatives to Zepbound?

With no generic to wait for, the real choices are a different brand, the same drug compounded, or Zepbound itself through a cheaper door. Which one fits depends on why Zepbound isn't working for you: price, insurance or needles.

• Cheapest FDA-approved option, paying cash: the Wegovy pill or Lilly's Foundayo pill, about $150 to $300 a month.
• You want to stay on tirzepatide but pay less: compounded tirzepatide, from about $130 to about $200 a month at the cheaper sellers. It is not FDA-approved.
• Your plan covers Zepbound: Lilly's savings card, as little as $25 a month, beats every alternative here.
• You have type 2 diabetes and commercial insurance: Mounjaro with Lilly's savings card, as little as $25 a month.
• You're on Medicare: the GLP-1 Bridge, $50 a month for the Zepbound KwikPen, Wegovy or Foundayo if you qualify.

Is there a generic Zepbound?

No, and not soon. No generic tirzepatide has been approved. Lilly's patents on tirzepatide run into 2036, according to drugs.com's patent listing. Sandoz said on June 29, 2026 that the FDA accepted two of its generic applications for review. Amneal and Adalvo announced the same for theirs on July 8, 2026.

"Accepted for review" is a long way from "on the shelf." A generic still has to get past Lilly's patents, through a court challenge or a licensing deal. Neither has happened. If you're waiting for a generic before tackling cost, it won't come this year. The insurance and savings card routes are on Zepbound cost.

Compounded tirzepatide: the same drug for less, but is it legal?

This is the closest match to Zepbound, because it is the same active drug, tirzepatide. A licensed 503A compounding pharmacy mixes it for one named patient. Lilly doesn't make it, and it isn't an FDA-approved finished drug.

Prices vary a lot by seller. Curex includes the visit, medicine and shipping, with no membership. It charges about $250 to $400 a month month to month, by form and dose, or from about $200 on a prepaid year. Eden charges about $130 a month at every dose, though it got an FDA warning letter in June 2026. All sellers are compared on compounded tirzepatide providers.

The legal ground narrowed in 2025. The FDA declared the tirzepatide shortage over in December 2024. Large 503B outsourcing facilities had to stop making copies by March 19, 2025. A 503A pharmacy can still compound it for one patient when a prescriber documents a medical reason, such as an allergy to an ingredient in Zepbound. Cost alone doesn't count.

On April 30, 2026, the FDA also proposed not adding tirzepatide to the 503B bulks list, the list of drugs those large facilities may compound. Comments closed on July 30, 2026, and no final decision had been published by early October. That proposal concerns 503B facilities only, not the 503A pharmacies most online sellers use.

Wegovy vs. Zepbound: is semaglutide a real substitute or a downgrade?

Wegovy is a real substitute, with a different average result. Both are GLP-1 drugs, but tirzepatide also acts on a second hormone receptor, GIP. In SURMOUNT-5, the head-to-head trial, people lost about 20% of their weight on tirzepatide at 72 weeks, against about 14% on semaglutide.

A stronger 7.2 mg dose, Wegovy HD, was approved in March 2026. In its own trial, STEP UP, people on 7.2 mg lost about 18.7% of their weight, against 15.6% on 2.4 mg and 3.9% on placebo. That narrows the gap without closing it. The figures come from different trials, and no one has tested tirzepatide against the 7.2 mg dose.

Wegovy's edge is price and format. The Wegovy pill costs about $150, then $200, then about $300 a month, below Zepbound at each matching month of a normal start. The Wegovy pen costs about $350 a month. That's more than Zepbound's 2.5 mg start at about $300, but less than its about $450 from 7.5 mg. New patients pay about $200 for each of the first two pen fills, through December 31, 2026. With commercial insurance that covers Wegovy, the savings card brings it to as little as $25. See Wegovy cost for every route.

Foundayo: Lilly's pill alternative

Foundayo is a daily GLP-1 pill from Lilly, the maker of Zepbound. Its drug, orforglipron, is not tirzepatide. Paying Lilly directly, it costs about $150 a month to start and about $300 from the 9 mg dose. The low-dose discounts end December 31, 2026. With a commercial plan that covers it, Lilly's savings card can bring it to as little as $25. The details are on Foundayo cost.

Mounjaro vs. Zepbound: same drug, different insurance door

Mounjaro and Zepbound are the same drug, tirzepatide, from the same maker, at the same strengths. Only the FDA approval differs. Mounjaro is approved for type 2 diabetes, and Zepbound for weight management. That split decides price and access.

If you have type 2 diabetes and a commercial plan covers Mounjaro for it, Lilly's savings card can bring it to as little as $25 a month. A weight-loss-only prescription doesn't qualify, and government plans are excluded. Without coverage, Lilly sells Mounjaro for about $500 a month at every dose. Zepbound's self-pay price is lower, about $300 to $450. So for cash payers, Zepbound is the better buy. See Mounjaro cost for the full breakdown.

Zepbound on Medicare: the GLP-1 Bridge

Medicare drug plans can't cover drugs used only for weight loss. Medicare's GLP-1 Bridge is the exception. From July 1, 2026 to December 31, 2027, it covers the Zepbound KwikPen, the Wegovy pen or pill, and Foundayo for $50 a month. You need Part D or Medicare Advantage and must meet its BMI and health rules.

Is Zepbound actually out of stock right now?

Less often than compounding ads suggest. The FDA declared the tirzepatide shortage over in December 2024. Single doses can still run short at one pharmacy. But a blanket claim that Zepbound is out of stock is usually a sales pitch for a compounded version. If your pharmacy is out, try Lilly's self-pay pharmacy or another local pharmacy before assuming it's gone everywhere.

OTC "GLP-1" pills, patches and gummies: what they actually are

No over-the-counter product sold as a "natural GLP-1" comes close to what tirzepatide or semaglutide do. The most common ingredient is berberine, a plant extract sold as a dietary supplement, not a drug. That means the FDA never checks its purity, strength or results before it's sold.

Berberine has modest evidence for blood sugar. It works more like metformin than like a GLP-1 drug. Its weight-loss effect in trials is about 1 to 4 kilograms on average, far below tirzepatide's roughly 20% of body weight. "Nature's Ozempic" is a marketing label, not a description of how it works.

"GLP-1 patches" deserve a firmer no. Estradiol, the hormone in HRT patches, is a small molecule that passes through skin. GLP-1 drugs are peptides, large chains that intact skin blocks. A patch has no way to deliver tirzepatide or semaglutide into your blood. Gummies and drops with "GLP-1" in the name usually repackage berberine, chromium or glucomannan.

• No prescription, visit or lab work before you buy
• Sold on Amazon, TikTok Shop or through an ad, not by a licensed clinic or pharmacy
• "GLP-1" in the name, with no named drug or dose on the label
• A patch, gummy or drop that claims to contain tirzepatide or semaglutide
• A price far below even compounded tirzepatide for "the same results"

Not every supplement here is a scam. But treating one as a cheaper swap for Zepbound is the one substitution on this page that doesn't hold up.

So which Zepbound alternative makes sense for you?

• You pay cash and want an FDA-approved drug: the Wegovy pill or Foundayo, about $150 to $300 a month. Zepbound has no pill.
• You want the same drug for less: compounded tirzepatide, from about $130 to $200 a month at the cheaper sellers. Know the narrower legal footing first.
• Your insurance covers Zepbound: the savings card, as little as $25 a month, beats everything here.
• You have type 2 diabetes and commercial insurance: ask about Mounjaro and Lilly's savings card.
• You're on Medicare: check the GLP-1 Bridge, $50 a month if you qualify.
• You want the strongest trial result: Zepbound itself still has the only head-to-head win, at whichever price you qualify for.
• You're tempted by an OTC "GLP-1" product: it isn't a substitute for any option above.

What does a year cost on each alternative?

These first-year totals follow the label's normal dose steps, not the starting price. Zepbound and the Wegovy pen come in 28-day boxes, so a year takes 13 fills.

• Zepbound or Wegovy with insurance and a savings card: about $325 a year, if your copay stays within the card's limits
• Medicare GLP-1 Bridge: about $600 to $650 a year at $50 a month
• Compounded tirzepatide, Curex prepaid year: about $2,390 at the lowest dose, about $3,590 at higher doses
• Foundayo, Lilly self-pay: about $3,190 in the first year
• Wegovy pill, NovoCare: about $3,340 in the first year
• Wegovy pen, NovoCare: about $4,240 in the first year with the two intro fills
• Zepbound, Lilly self-pay: about $5,100 in the first year at 5 mg, about $5,650 moving up to 7.5 mg or more
• Mounjaro, Lilly self-pay: about $6,490 a year

Two Lilly rules can push the Zepbound total up. The self-pay terms cover up to 11 KwikPen fills a year, and a full year takes 13. From 7.5 mg, each refill must come within 45 days, or the price rises to about $500 at 7.5 mg and about $700 from 10 mg. The self-pay offer ends December 31, 2026.